Literature DB >> 457877

Osmotic blood-brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery.

E A Neuwelt, K R Maravilla, E P Frenkel, S I Rapaport, S A Hill, P A Barnett.   

Abstract

The present study describes a canine model of transient reversible blood-brain barrier disruption with hyperosmolar mannitol infusion into the internal carotid artery. Studies in this model show that osmotic blood-brain barrier disruption before intracarotid infusion of methotrexate results in markedly elevated (therapeutic) levels of drug in the ipsilateral cerebral hemisphere. Levels in the cerebrospinal fluid correlate poorly and inconsistently with brain levels. Computerized tomograms in this canine model provide a noninvasive monitor of the degree, time-course, and localization of osmotic blood-brain barrier disruption.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 457877      PMCID： PMC372166          DOI： 10.1172/JCI109509

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  10 in total

1.  Chemotherapy of brain tumors.

Authors:  N A Vick; J D Khandekar; D D Bigner
Journal:  Arch Neurol       Date:  1977-09

2.  Uptake and distribution of 3 H-methotrexate by the murine ependymoblastoma.

Authors:  V A Levin; T P Clancy; J I Ausman; D P Rall
Journal:  J Natl Cancer Inst       Date:  1972-04       Impact factor: 13.506

3.  Equi-osmolal opening of the blood-brain barrier in the rabbit by different contrast media.

Authors:  S I Rapoport; H K Thompson; J M Bidinger
Journal:  Acta Radiol Diagn (Stockh)       Date:  1974-01

4.  Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule.

Authors:  R S Benjamin; P H Wiernik; N R Bachur
Journal:  Cancer       Date:  1974-01       Impact factor: 6.860

5.  Chemotherapy of brain tumors. Uptake of tritiated methotrexate by a transplantable intracerebral ependymoblastoma in mice.

Authors:  C H Tator
Journal:  J Neurosurg       Date:  1972-07       Impact factor: 5.115

6.  Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.

Authors:  R G Stoller; K R Hande; S A Jacobs; S A Rosenberg; B A Chabner
Journal:  N Engl J Med       Date:  1977-09-22       Impact factor: 91.245

7.  Management of central nervous system metastases.

Authors:  J B Posner
Journal:  Semin Oncol       Date:  1977-03       Impact factor: 4.929

8.  Direct administration of methotrexate into the central nervous system of primates. Part 1: Distribution and degradation of methotrexate in nervous and systemic tissue after intraventricular injection.

Authors:  H K Kimelberg; D Kung; R E Watson; F L Reiss; S M Biddlecome; R S Bourke
Journal:  J Neurosurg       Date:  1978-06       Impact factor: 5.115

9.  Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.

Authors:  W R Shapiro; D F Young; B M Mehta
Journal:  N Engl J Med       Date:  1975-07-24       Impact factor: 91.245

10.  Methotrexate in blood, urine, and cerebrospinal fluid of children receiving high doses by infusion.

Authors:  Y Wang; E Lantin; W W Sutow
Journal:  Clin Chem       Date:  1976-07       Impact factor: 8.327
  10 in total
  31 in total

Review 1.  Intra-arterial chemotherapy for malignant gliomas: a critical analysis.

Authors:  J-K Burkhardt; H A Riina; B J Shin; J A Moliterno; C P Hofstetter; J A Boockvar
Journal:  Interv Neuroradiol       Date:  2011-10-17       Impact factor: 1.610

2.  Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells.

Authors:  Rachel C Brown; Andrew P Morris; Roger G O'Neil
Journal:  Brain Res       Date:  2006-12-12       Impact factor: 3.252

3.  Effects of acoustic parameters and ultrasound contrast agent dose on focused-ultrasound induced blood-brain barrier disruption.

Authors:  Nathan McDannold; Natalia Vykhodtseva; Kullervo Hynynen
Journal:  Ultrasound Med Biol       Date:  2008-02-21       Impact factor: 2.998

Review 4.  Improving CNS Delivery to Brain Metastases by Blood-Tumor Barrier Disruption.

Authors:  Samuel A Sprowls; Tasneem A Arsiwala; Jacob R Bumgarner; Neal Shah; Sundus S Lateef; Brooke N Kielkowski; Paul R Lockman
Journal:  Trends Cancer       Date:  2019-07-20

5.  Modulation of intercellular junctions by cyclic-ADT peptides as a method to reversibly increase blood-brain barrier permeability.

Authors:  Marlyn D Laksitorini; Paul K Kiptoo; Ngoc H On; James A Thliveris; Donald W Miller; Teruna J Siahaan
Journal:  J Pharm Sci       Date:  2015-01-12       Impact factor: 3.534

Review 6.  Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going.

Authors:  Randy S D'Amico; Deepak Khatri; Noah Reichman; Nitesh V Patel; Tamika Wong; Sherese R Fralin; Mona Li; Jason A Ellis; Rafael Ortiz; David J Langer; John A Boockvar
Journal:  J Neurooncol       Date:  2020-02-19       Impact factor: 4.130

Review 7.  Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers.

Authors:  Marlyn Laksitorini; Vivitri D Prasasty; Paul K Kiptoo; Teruna J Siahaan
Journal:  Ther Deliv       Date:  2014-10

8.  Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases.

Authors:  E A Neuwelt; S A Dahlborg
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

9.  Impact of drug size on brain tumor and brain parenchyma delivery after a blood-brain barrier disruption.

Authors:  Marie Blanchette; Luc Tremblay; Martin Lepage; David Fortin
Journal:  J Cereb Blood Flow Metab       Date:  2014-02-12       Impact factor: 6.200

Review 10.  Stereotactic modulation of blood-brain barrier permeability to enhance drug delivery.

Authors:  Geoff Appelboom; Alexandre Detappe; Melissa LoPresti; Sijumon Kunjachan; Stefan Mitrasinovic; Serge Goldman; Steve D Chang; Olivier Tillement
Journal:  Neuro Oncol       Date:  2016-07-11       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.